Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure

Cardiovascular disease is the leading cause of death in Chronic kidney disease patients. This study tries to identify circulating endothelial microparticles {MPs} [such as Cadherin 5 and Anexin V] in CKD patients with and without IHD as potential new risk factors of atherosclerotic vascular disease. This study was carried out in Theodor Bilharz Research Institute [TBRI] on 60 patients with chronic kidney disease on maintenance hemodialysis. They were 41 male and 19 females selected from hemodialysis unit in TBRI. They were further subclassified into the following two groups according to the Echocardiography and Electrocardiogram (ECG) to 25 patients of chronic kidney disease without cardiac complications (17 males, 8 females and ages were 53.5±9.9 years) and 35 patients of chronic kidney disease with cardiac complications (24 males, 11 females and ages were 57.5±7.4 years). Twenty healthy subjects were selected as healthy control, their age 50±9 years. Cadherin 5 & Annexin V Were done by enzyme linked immunosorbant assay (ELISA). The mean cadherin 5 levels in CKD with ischemic HD, CKD without ischemic HD and control group were 86.99±21.51, 33.21± 8.65 and 2.63±1.47 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p<0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p<0.01). As regard to the mean annexin v levels in CKD with ischemic HD, CKD without ischemic HD and control group were 83.73±22.64, 28.51±9.73 and 0.47±0.36 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p<0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p<0.01). Endothelial dysfunction leading to atherosclerotic vascular disease in patients with CKD can be assessed quantitatively by measurement of plasma levels of endothelial microparticles such as CD144-EMP (Cadherin 5) and Annexin V.